866-997-4948(US-Canada Toll Free)

Hypoglycemia - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Metabolic Disorders

No. of Pages : 51 Pages


Global Markets Directs, \'Hypoglycemia Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hypoglycemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypoglycemia. Hypoglycemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hypoglycemia.
  • A review of the Hypoglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hypoglycemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hypoglycemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypoglycemia Overview 6
Therapeutics Development 7
Pipeline Products for Hypoglycemia - Overview 7
Pipeline Products for Hypoglycemia - Comparative Analysis 8
Hypoglycemia - Therapeutics under Development by Companies 9
Hypoglycemia - Therapeutics under Investigation by Universities/Institutes 10
Hypoglycemia - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hypoglycemia - Products under Development by Companies 13
Hypoglycemia - Products under Investigation by Universities/Institutes 14
Hypoglycemia - Companies Involved in Therapeutics Development 15
F. Hoffmann-La Roche Ltd. 15
SkyePharma PLC 16
Zealand Pharma A/S 17
USV Limited 18
Amunix, Inc. 19
XERIS Pharmaceuticals, Inc. 20
Hypoglycemia - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Assessment by Therapeutic Class 28
Drug Profiles 30
GLP-1 (7-36) Amide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SKP-1052 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
glucagon XeriSol - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
glucagon - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MAR-531 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
glucagon biosimilar - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ZP-GA-1 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Hypoglycemia - Recent Pipeline Updates 38
Hypoglycemia - Dormant Projects 39
Hypoglycemia - Product Development Milestones 40
Featured News & Press Releases 40
Dec 03, 2013: IDegLira demonstrates superior glycaemic control and weight loss with a low rate of hypoglycaemia for patients uncontrolled on basal insulin 40
Oct 17, 2013: Xeris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation 41
Sep 27, 2013: IDegLira improves glycaemic control throughout the day with no weight gain and a low rate of hypoglycaemia 42
Sep 26, 2013: New Hypoglycemia and Pancreatitis Subanalyses from the Onglyza SAVOR Cardiovascular Outcomes Trial Presented at the 49th Annual Meeting of the European Association for the Study of Diabetes 43
Jul 03, 2013: Biodel to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference 46
Jun 22, 2013: Zealand Pharma Presents Preclinical Data On Hypoglycemic Drug ZP-GA-1 At 73rd ADA Scientific Sessions 46
Jun 06, 2013: Biodel Plans To Submit New Drug Application For Glucagon Rescue Product Candidate To Treat Severe Hypoglycemia 47
Dec 06, 2012: Biodel\'s Glucagon Obtains FDA Orphan Drug Designation To Prevent Hypoglycemia In Congenital Hyperinsulinism Population 48
Nov 09, 2012: Novo Nordisk\'s Insulin Degludec/Insulin Aspart Receives Positive Vote For Approval From FDA Advisory Committee 49
Nov 09, 2012: Novo Nordisk\'s Insulin degludec Receives Positive Vote For Approval From FDA Advisory Committee 49

Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Table


Number of Products under Development for Hypoglycemia, H2 2013 7
Number of Products under Development for Hypoglycemia - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
Hypoglycemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2013 15
Hypoglycemia - Pipeline by SkyePharma PLC, H2 2013 16
Hypoglycemia - Pipeline by Zealand Pharma A/S, H2 2013 17
Hypoglycemia - Pipeline by USV Limited, H2 2013 18
Hypoglycemia - Pipeline by Amunix, Inc., H2 2013 19
Hypoglycemia - Pipeline by XERIS Pharmaceuticals, Inc., H2 2013 20
Assessment by Monotherapy Products, H2 2013 21
Number of Products by Stage and Target, H2 2013 22
Number of Products by Stage and Mechanism of Action, H2 2013 23
Number of Products by Stage and Route of Administration, H2 2013 25
Number of Products by Stage and Molecule Type, H2 2013 27
Number of Products by Stage and Therapeutic Class, H2 2013 29
Hypoglycemia Therapeutics - Recent Pipeline Updates, H2 2013 38
Hypoglycemia - Dormant Projects, H2 2013 39

List of Chart


Number of Products under Development for Hypoglycemia, H2 2013 7
Number of Products under Development for Hypoglycemia - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Clinical Stage Development, H2 2013 11
Assessment by Monotherapy Products, H2 2013 21
Number of Products by Stage and Top 10 Target, H2 2013 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 23
Number of Products by Top 10 Route of Administration, H2 2013 24
Number of Products by Stage and Top 10 Route of Administration, H2 2013 25
Number of Products by Top 10 Molecule Type, H2 2013 26
Number of Products by Stage and Top 10 Molecule Type, H2 2013 27
Number of Products by Top 10 Therapeutic Class, H2 2013 28
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *